Damora Therapeutics (DMRA) EBT (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly EBT came in at -$27.7 million in Q1 2026, down 996.05% YoY from $3.1 million in Q1 2025, and up 85.91% on a QoQ basis from -$196.8 million in Q4 2025.
Damora Therapeutics (DMRA) EBT (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of EBT data on file, last reported at -$27.7 million in Q1 2026.
- Quarterly EBT fell 996.05% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.1 million (down 1152.65% YoY) and the FY2025 annual result came in at -$205.9 million, down 862.37% from the prior year.
- EBT climbed to -$27.7 million in Q1 2026, from -$196.8 million in the prior quarter.
- In the past five years, EBT ranged from a high of $1.7 million in Q4 2023 to a low of -$196.8 million in Q4 2025.
- A 5-year average of -$20.5 million and a median of -$8.1 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT surged 112.19% — and 2025, when it tumbled 2816.46%.
- Tracing DMRA's EBT over 5 years: stood at -$13.7 million in 2022, then surged by 112.19% to $1.7 million in 2023, then slumped by 504.86% to -$6.7 million in 2024, then plunged by 2816.46% to -$196.8 million in 2025, then jumped by 85.91% to -$27.7 million in 2026.
- The last three EBT figures came in at -$27.7 million (Q1 2026), -$196.8 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -30.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.92 Mn |
| Mar 31, 2026 | -27.74 Mn |
| Dec 31, 2025 | -196.83 Mn |
| Sep 30, 2025 | -3.13 Mn |
| Jun 30, 2025 | -3.43 Mn |
| Mar 31, 2025 | -2.53 Mn |
| Dec 31, 2024 | -6.75 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | -5.30 Mn |
| Mar 31, 2024 | -5.48 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | -8.14 Mn |
| Jun 30, 2023 | -10.74 Mn |
| Mar 31, 2023 | -14.92 Mn |
| Dec 31, 2022 | -13.68 Mn |
| Sep 30, 2022 | -13.76 Mn |
| Jun 30, 2022 | -17.24 Mn |
| Mar 31, 2022 | -17.28 Mn |
| Dec 31, 2021 | -13.58 Mn |
| Sep 30, 2021 | -15.00 Mn |